Keywords: houghten, obesity, drug, pharmaceuticals, completed, dose-ranging, trial

Houghten Obesity Drug

Article | 09 December 1996

- Houghten Pharmaceuticals has completed a dose-ranging trial with HP 228, a cytokine-regulating agent, in obese type II diabetics. Administered twice-daily at ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in